Want to see EOLS full AI Analyst Report?
EOLS Stock Chart & Stats
$4.69
-$0.47(-4.38%)
At close: 4:00 PM EST
$4.69
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$3.86 - $10.20
Previous CloseN/A
Volume344.54K
Average Volume (3M)751.27K
Market Cap
$447.15M
Enterprise Value$558.97M
Total Cash (Recent Filing)$49.79M
Total Debt (Recent Filing)$164.90M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding65,854,750
10 Day Avg. Volume759,703
30 Day Avg. Volume751,269
Financial Highlights & Ratios
PEG Ratio6.73
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-9.38
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue1.85
Enterprise Value/Gross Profit2.83
Enterprise Value/Ebitda-39.84
Forecast
1Y Price Target
$14.50Price Target Upside209.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$330.45M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Healthy Gross MarginsSustained multi-year top-line expansion (TTM revenue up ~155%) combined with a consistently high ~65% gross margin implies durable product economics and pricing power. This mix supports scalable operating leverage and long-term margin sustainability as volume grows and fixed costs dilute.
Profitability Momentum And GuidanceReturning to positive adjusted EBITDA and reiterating full-year profitability guidance signals improving operating discipline and near-term self-sustainability. If maintained, this reduces external funding dependence, enables reinvestment in growth initiatives, and validates operating leverage from stable gross margins.
Capital‑Efficient Portfolio Expansion (Profhilo)The IBSA Profhilo deal broadens the addressable injectable market into skin‑quality treatments without onerous upfront costs. A transfer‑price, capital‑efficient structure preserves margins while diversifying the portfolio, supporting sustainable practitioner adoption and long‑term revenue mix improvement.
Bears Say
Negative Equity And Elevated LeverageNegative equity and a materially higher debt balance weaken financial flexibility and raise refinancing and covenant risk. This structural leverage constraint limits the company's ability to fund growth organically or absorb shocks, making capital markets access and cost of capital potential long‑term headwinds.
Negative Operating & Free Cash FlowPersistently negative operating and free cash flow forces reliance on external financing, increasing dilution or debt service obligations. Even with improving EBITDA, negative cash generation constrains reinvestment, heightens liquidity risk if capital availability tightens, and pressures long‑term financial durability.
Product Concentration & Competitive PressureRevenue remains concentrated in Jeuveau, with newer products still small, exposing the company to competitive displacement and market share volatility. Ongoing entrant activity and incumbents in filler and neurotoxin markets require sustained commercial investment to defend share, pressuring margins and growth durability.
Evolus News
EOLS FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was $3.86 and its highest was $10.20 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is $447.15M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 25 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on May 04, 2026. The company reported -$0.046 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.067.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 65,854,750 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of -$0.046 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went up 14.158%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (209.17% Upside)
$14.50 (209.17% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 4.7%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.08%
12-Months-Change
Fundamentals
Return on Equity
174.92%
Trailing 12-Months
Asset Growth
3.41%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly constructive picture: revenue growth (Q1 +7%), healthy margins (adjusted gross margin 68%), expanding commercial footprint and loyalty (Rewards members +27% YoY), and a return to positive adjusted EBITDA ($0.6M) alongside reiterated full-year guidance and planned product launches (Esteem in Europe, Sculp FDA in Q4). Key risks include timing/seasonality comparatives, a newly announced 15% South Korea tariff on certain products, a still-small contribution from Evolisse amid a soft filler market, and continued competitive entrants. On balance, the operational improvements, profitability momentum, and clear pipeline/launch cadence outweigh the cited headwinds.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(209.17% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.13% Insiders
7.96% Mutual Funds
1.55% Other Institutional Investors
75.36% Public Companies and
Individual Investors